Bradley Rosenberg, MD
Family Medicine · Torrington, CTNPI 1679591168
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 618 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AstraZeneca at 30.7% of the total. Reporting peaked in 2024 at $3,321 and has fallen 68.2% since, to $1,056 in 2025. Among family medicine clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 618 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- AbbVie$2K
- GSK$815
- Pfizer$783
- Lilly USA, LLC$608
- Boehringer Ingelheim$584
- plus $3K from 24 others
What the payments were for
- Food & beverage$10,72599%
- Education$1631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 95 | $3,347 |
| AbbVie(2 entities) | 210 | $1,985 |
| GSK | 43 | $815 |
| Pfizer | 54 | $783 |
| Lilly USA, LLC | 31 | $608 |
| Boehringer Ingelheim | 32 | $584 |
| Novo Nordisk | 46 | $583 |
| Amgen(2 entities) | 17 | $324 |
| Phathom Pharmaceuticals, Inc. | 7 | $270 |
| Amarin Pharma, Inc. | 14 | $244 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $158 |
| Bayer | 7 | $135 |
| Corcept Therapeutics | 6 | $134 |
| Azurity Pharmaceuticals, Inc. | 6 | $128 |
| Johnson & Johnson | 6 | $110 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $88 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $87 |
| Lundbeck LLC | 4 | $85 |
| Idorsia Pharmaceuticals US Inc | 4 | $76 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
| Arbor Pharmaceuticals, Inc. | 3 | $51 |
| Amneal Pharmaceuticals LLC | 2 | $49 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Assertio Therapeutics, Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Merck | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Impel Pharmaceuticals Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,888 in reported general payments places this provider in the 90th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 85 | $87,161 |
| FarxigaDapagliflozin Propanediol | 58 | $82,330 |
| JardianceEmpagliflozin | 55 | $80,832 |
| EliquisApixaban | 70 | $65,603 |
| OzempicSemaglutide | 63 | $62,842 |
| RybelsusSemaglutide | 24 | $37,976 |
| JanuviaSitagliptin Phosphate | 19 | $30,361 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $27,843 |
| XareltoRivaroxaban | 18 | $27,132 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $19,564 |
| VascepaIcosapent Ethyl | 18 | $18,400 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,712 |
| SynthroidLevothyroxine Sodium | 63 | $5,931 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $5,646 |
| Atorvastatin Calcium | 645 | $4,955 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $583 | $100,81887 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $3,347 | $92,04173 claims |
| Lilly USA, LLCMounjaro | $608 | $87,16185 claims |
| Boehringer IngelheimJardiance | $584 | $80,83255 claims |
| PfizerEliquis | $783 | $65,60370 claims |
| MerckJanuvia, Janumet Xr | $21 | $58,20437 claims |
| Johnson & JohnsonXarelto | $110 | $27,13218 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $815 | $25,21045 claims |
| AbbVieSynthroid | $1,985 | $5,93163 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $49 | $2,604227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Torrington
- Elizabeth GalanTorrington$17K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
- Helar CamposNew London$29K
- Kristin GianniniVernon$28K
- Sanjeev RaoBridgeport$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.